Lilly’s (LLY) Taltz Gets Approval for Label Expansion in US
Eli Lilly and Company LLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults. We note that Taltz is presently approved for treating moderate-to-severe plaque psoriasis in adults who can have systemic therapy or phototherapy. The drug has grown more than 50% in the first nine months of 2017 and contributed significantly to revenues and volumes. […]